1,396
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models

, , , , , , & show all
Pages 2780-2786 | Received 13 Jun 2015, Accepted 07 Aug 2015, Published online: 31 Aug 2015

References

  • Bobo RH, Laske DW, Akbasak A, et al. (1994). Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076–80
  • Chamberlain MC. (2002). Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 56:183–8
  • Chen MY, Lonser RR, Morrison PF, et al. (1999). Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90:315–20
  • Cloughesy TF, Filka E, Kuhn J, et al. (2003). Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97:2381–6
  • Eberling JL, Jagust WJ, Christine CW, et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:1980–3
  • Friedman HS, Petros WP, Friedman AH, et al. (1999). Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–25
  • Gill SS, Patel NK, Hotton GR, et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589–95
  • Groothuis DR. (2000). The blood–brain and blood–tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2:45–59
  • Huynh GH, Deen DF, Szoka FC Jr. (2006). Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 110:236–59
  • Inoue T, Yamashita Y, Nishihara M, et al. (2009). Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models. Neuro Oncol 11:151–7
  • Kikuchi T, Saito R, Sugiyama S, et al. (2008). Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models. J Neurosurg 109:867–73
  • Koizumi F, Kitagawa M, Negishi T, et al. (2006). Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66:10048–56
  • Kunwar S. (2003). Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88:105–11
  • Kunwar S, Chang S, Westphal M, et al., PRECISE Study Group. (2010). Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12:871–81
  • Kuroda J, Kuratsu J, Yasunaga M, et al. (2009). Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 124:2505–11
  • Kuroda J, Kuratsu J, Yasunaga M, et al. (2010). Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin Cancer Res 16:521–9
  • Mardor Y, Roth Y, Lidar Z, et al. (2001). Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61:4971–3
  • Matsumura Y. (2011). Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 63:184–92
  • Prados MD, Lamborn K, Yung WK, et al., North American Brain Tumor Consortium. (2006). A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8:189–93
  • Saito R, Bringas JR, McKnight TR, et al. (2004). Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64:2572–9
  • Saito R, Bringas JR, Panner A, et al. (2004). Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 64:6858–62
  • Saito R, Krauze MT, Noble CO, et al. (2006). Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods 154:225–32
  • Sampson JH, Archer G, Pedain C, et al., PRECISE Trial Investigators. (2010). Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113:301–9
  • Sawamura Y, Shirato H, de Tribolet N. (1999). Recent advances in the treatment of central nervous system germ cell tumors. Adv Tech Stand Neurosurg 25:141–59
  • Yun J, Rothrock RJ, Canoll P, Bruce JN. (2013). Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J Drug Deliv 2013:107573
  • Zhang R, Saito R, Mano Y, et al. (2013). Concentration rather than dose defines the local brain toxicity of agents that are effectively distributed by convection-enhanced delivery. J Neurosci Methods 222:131–7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.